A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan.

[1]  R. Bellman,et al.  On structural identifiability , 1970 .

[2]  A. Krener,et al.  Nonlinear controllability and observability , 1977 .

[3]  H. Pohjanpalo.  System identifiability based on the power series expansion of the solution , 1978 .

[4]  Eric Walter,et al.  Identifiability of State Space Models , 1982 .

[5]  Keith Godfrey,et al.  Compartmental Models and Their Application , 1983 .

[6]  J. Jacquez.  Compartmental analysis in biology and medicine , 1985 .

[7]  J. DiStefano,et al.  Identifiability of Model Parameter , 1985 .

[8]  T. Tarn,et al.  New results for identifiability of nonlinear systems , 1987 .

[9]  Eric Walter,et al.  Identifiability of parametric models , 1987 .

[10]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[11]  H. Rabitz,et al.  Similarity transformation approach to identifiability analysis of nonlinear compartmental models. , 1989, Mathematical biosciences.

[12]  L. Grochow,et al.  Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. , 1992, Cancer research.

[13]  J. Verweij,et al.  Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. , 1996, Journal of chromatography. B, Biomedical applications.

[14]  R. Larsson,et al.  Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. , 1997, British Journal of Cancer.

[15]  P. Seetharamulu,et al.  Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. , 1998, Cancer research.

[16]  M. Manfait,et al.  Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. , 1998, Biochimica et biophysica acta.

[17]  J. O’Leary,et al.  Camptothecins: a review of their development and schedules of administration. , 1998, European journal of cancer.

[18]  Y. Pommier,et al.  Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. , 1999, Cancer research.

[19]  J. Lakowicz,et al.  Fluorescence Spectral Properties of the Anticancer Drug Topotecan by Steady‐State and Frequency Domain Fluorometry with One‐Photon and Multi‐Photon Excitation , 1999, Photochemistry and photobiology.

[20]  D. Ormrod,et al.  Topotecan , 1999, Drugs.

[21]  D. Cooke,et al.  A Basic Course in Statistics , 2000 .

[22]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[23]  T. Litman,et al.  The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. , 2000, Biochemical and biophysical research communications.

[24]  C. Bailly.  Topoisomerase I poisons and suppressors as anticancer drugs. , 2000, Current medicinal chemistry.

[25]  L. Ratner,et al.  Multidrug resistance transporters and modulation , 2000, Current opinion in oncology.

[26]  Rongling Wu,et al.  Modeling with Compartments , 2002 .

[27]  Keith R. Godfrey,et al.  Identifiability of uncontrolled nonlinear rational systems , 2002, Autom..

[28]  M. J. Chapman,et al.  THE STRUCTURAL IDENTIFIABILITY OF A GENERAL EPIDEMIC (SIR) MODEL WITH SEASONAL FORCING , 2002 .

[29]  J. Supko,et al.  Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  K. Godfrey,et al.  Optimal tumor targeting by antibodies: Development of a mathematical model , 1991, Journal of Pharmacokinetics and Biopharmaceutics.